Changes in biomarkers of inflammation and angiogenesis during androgen deprivation therapy for prostate cancer

Oncologist

Volumn 17, Issue 2, 2012, Pages 212-219

  Saylor, Philip J ^a   Kozak, Kevin R ^b,c   Smith, Matthew R ^a   Ancukiewicz, Marek A ^c   Efstathiou, Jason A ^c   Zietman, Anthony L ^c   Jain, Rakesh K ^c   Duda, Dan G ^c  

^a MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BICALUTAMIDE; BIOLOGICAL MARKER; C REACTIVE PROTEIN; FIBROBLAST GROWTH FACTOR 2; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LEUPRORELIN; LUPRONDEPOT; PLACENTAL GROWTH FACTOR; PROSTATE SPECIFIC ANTIGEN; SERUM AMYLOID A; STEM CELL FACTOR RECEPTOR; STROMAL CELL DERIVED FACTOR 1ALPHA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ADULT; ADVANCED CANCER; AGED; ANDROGEN DEPRIVATION THERAPY; ANGIOGENESIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPLORATORY RESEARCH; HUMAN; INFLAMMATION; MALE; PRIORITY JOURNAL; PROSTATE CANCER; RECURRENT CANCER;

AGED; ANDROGEN ANTAGONISTS; BIOLOGICAL MARKERS; CHEMOKINE CXCL12; FIBROBLAST GROWTH FACTOR 2; HUMANS; INFLAMMATION; INTERLEUKIN-1BETA; INTERLEUKIN-6; INTERLEUKIN-8; MALE; NEOVASCULARIZATION, PHYSIOLOGIC; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 84863119929     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2011-0321     Document Type: Article

References (46)

1. Zietman A. Evidence-based medicine, conscience-based medicine, and the management of low-risk prostate cancer. J Clin Oncol 2009;27: 4935-4936.
2. Surveillance, Epidemiology, and End Results (SEER). SEER Stat Fact Sheets: Prostate Cancer. Available at http://seer.cancer.gov/statfacts/html/ prost.html, accessed January 10, 2012.
3. Ferrer FA, Miller LJ, Andrawis RI et al. Vascular endothelial growth factor (VEGF) expression in human prostate cancer: In situ and in vitro expression of VEGF by human prostate cancer cells. J Urol 1997;157:2329-2333.
4. Mazzucchelli R, Montironi R, Santinelli A et al. Vascular endothelial growth factor expression and capillary architecture in high-grade PIN and prostate cancer in untreated and androgen-ablated patients. Prostate 2000;45:72-79.
5. Ferrer FA, Miller LJ, Andrawis RI et al. Angiogenesis and prostate cancer: In vivo and in vitro expression of angiogenesis factors by prostate cancer cells. Urology 1998;51:161-167.
6. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011;473:298-307.
7. Picus J, Halabi S, Kelly WK et al. A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer: Results from Cancer and Leukemia Group B Study 90006. Cancer 2011;117:526-533.
8. Kelly WK, Halabi S, Carducci MA et al. A randomized, double-blind, placebo-controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration-resistant prostate cancer (mCRPC): Survival results of CALGB 90401. J Clin Oncol 2010;28(18 suppl): Abstract LBA4511.
9. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420:860-867.
10. Kantoff PW, Higano CS, Shore ND et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363:411-422.
11. Jain RK, Safabakhsh N, Sckell A et al. Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: Role of vascular endothelial growth factor. Proc Natl Acad Sci U S A 1998;95:10820-10825.
12. Lopes CO, Callera F. Three-dimensional conformal radiotherapy in prostate cancer patients: Rise in interleukin 6 (IL-6) but not IL-2, IL-4, IL-5, tumor necrosis factor-α, MIP-1-α, and LIF levels. Int J Radiat Oncol Biol Phys 2011 Jun 1 [Epub ahead of print].
13. Kovacs CJ, Daly BM, Evans MJ et al. Cytokine profiles in patients receiving wide-field _ prostate boost radiotherapy (xRT) for adenocarcinoma of the prostate. Cytokine 2003;23:151-163.
14. Christensen E, Pintilie M, Evans KR et al. Longitudinal cytokine expression during IMRT for prostate cancer and acute treatment toxicity. Clin Cancer Res 2009;15:5576-5583.
15. Hurwitz MD, Kaur P, Nagaraja GM et al. Radiation therapy induces circulating serum Hsp72 in patients with prostate cancer. Radiother Oncol 2010;95:350-358.
16. Johnke RM, Edwards JM, Evans MJ et al. Circulating cytokine levels in prostate cancer patients undergoing radiation therapy: Influence of neoadjuvant total androgen suppression. In Vivo 2009; 23:827-833.
17. Maggio M, Basaria S, Ble A et al. Correlation between testosterone and the inflammatory marker soluble interleukin-6 receptor in older men. J Clin Endocrinol Metab 2006;91:345-347.
18. Malkin CJ, Pugh PJ, Jones RD et al. The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men. J Clin Endocrinol Metab 2004;89:3313-3318.
19. Khosla S, Atkinson EJ, Dunstan CR et al. Effect of estrogen versus testosterone on circulating osteoprotegerin and other cytokine levels in normal elderly men. J Clin Endocrinol Metab 2002;87: 1550-1554.
20. Maggio M, Blackford A, Taub D et al. Circulating inflammatory cytokine expression in men with prostate cancer undergoing androgen deprivation therapy. J Androl 2006;27:725-728.
21. Smith MR, Lee H, Fallon MA et al. Adipocytokines, obesity, and insulin resistance during combined androgen blockade for prostate cancer. Urology 2008;71:318-322.
22. Wise GJ, Marella VK, Talluri G et al. Cytokine variations in patients with hormone treated prostate cancer. J Urol 2000;164:722-725.
23. George DJ, Halabi S, Shepard TF et al. The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: Results from Cancer and Leukemia Group B 9480. Clin Cancer Res 2005;11: 1815-1820.
24. Pallares J, Rojo F, Iriarte J et al. Study of microvessel density and the expression of the angiogenic factors VEGF, bFGF and the receptors Flt-1 and FLK-1 in benign, premalignant and malignant prostate tissues. Histol Histopathol 2006;21:857-865.
25. Matsumoto K, Suzuki K, Koike H et al. Placental growth factor gene expression in human prostate cancer and benign prostate hyperplasia. Anticancer Res 2003;23:3767-3773.
26. Duque JL, Loughlin KR, Adam RM et al. Measurement of plasma levels of vascular endothelial growth factor in prostate cancer patients: Relationship with clinical stage, Gleason score, prostate volume, and serum prostate-specific antigen. Clinics (Sao Paulo) 2006;61:401-408.
27. Duque JL, Loughlin KR, Adam RM et al. Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer. Urology 1999;54:523-527.
28. Bok RA, Halabi S, Fei DT et al. Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: A Cancer and Leukemia Group B study. Cancer Res 2001;61: 2533-2536.
29. George DJ, Halabi S, Shepard TF et al. Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. Clin Cancer Res 2001;7: 1932-1936.
30. Milosevic M, Chung P, Parker C et al. Androgen withdrawal in patients reduces prostate cancer hypoxia: Implications for disease progression and radiation response. Cancer Res 2007;67:6022-6025.
31. Alonzi R, Padhani AR, Taylor NJ et al. Antivascular effects of neoadjuvant androgen deprivation for prostate cancer: An in vivo human study using susceptibility and relaxivity dynamic MRI. Int J Radiat Oncol Biol Phys 2011;80:721-727.
32. Shulman MJ, Karam JA, Benaim EA. Prostate-specific antigen doubling time predicts response to deferred antiandrogen therapy in men with androgen-independent prostate cancer. Urology 2004;63:732-736.
33. Keizman D, Huang P, Antonarakis ES et al. The change of PSA doubling time and its association with disease progression in patients with biochemically relapsed prostate cancer treated with intermittent androgen deprivation. Prostate 2011; 71:1608-1615.
34. Ferrara N. Vascular endothelial growth factor. Arterioscler Thromb Vasc Biol 2009;29:789-791.
35. De Falco S, Gigante B, Persico MG. Structure and function of placental growth factor. Trends Cardiovasc Medicine 2002;12:241-246.
36. Fischer C, Mazzone M, Jonckx B et al. FLT1 and its ligands VEGFB and PlGF: Drug targets for anti-angiogenic therapy? Nat Rev Cancer 2008;8: 942-956.
37. Wu FT, Stefanini MO, Mac Gabhann F et al. Asystems biology perspective on sVEGFR1: Its biological function, pathogenic role and therapeutic use. J Cell Mol Med 2010;14:528-552.
38. Ebos JM, Bocci G, Man S et al. A naturally occurring soluble form of vascular endothelial growth factor receptor 2 detected in mouse and human plasma. Mol Cancer Res 2004;2:315-326.
39. Presta M, Dell'Era P, Mitola S et al. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev 2005;16:159-178.
40. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: The multistep paradigm. Cell 1994;76:301-314.
41. Uhlar CM, Whitehead AS. Serum amyloid A, the major vertebrate acute-phase reactant. Eur J Biochem 1999;265:501-523.
42. Jensen LE, Whitehead AS. Regulation of serum amyloid A protein expression during the acutephase response. Biochem J 1998;334:489-503.
43. Heinrich PC, Behrmann I, Haan S et al. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 2003;374:1-20.
44. Turner AM, Bennett LG, Lin NL et al. Identification and characterization of a soluble c-kit receptor produced by human hematopoietic cell lines. Blood 1995;85:2052-2058.
45. Dahlen DD, Lin NL, Liu YC et al. Soluble Kit receptor blocks stem cell factor bioactivity in vitro. Leuk Res 2001;25:413-421.
46. Nakamura Y, Tajima F, Ishiga K et al. Soluble c-Kit receptor mobilizes hematopoietic stem cells to peripheral blood in mice. Exp Hematol 2004;32: 390-396.